Future treatment of chronic obstructive pulmonary disease

Monaldi Archives for Chest Disease - Pulmonary Series

Volumn 57, Issue 3-4, 2002, Pages 200-205

  Di Maria, Giuseppe ^a   Spicuzza, L ^a   Mazzarella, G ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Anti inflammatory treatment; Bronchodilator; COPD; Muco active drugs; Proteases inhibition

Indexed keywords

4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; ACETYLCYSTEINE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CCC 3; CHOLINERGIC RECEPTOR BLOCKING AGENT; CILOMILAST; DARIFENACIN; ELASTASE INHIBITOR; FORMOTEROL; GLUCOCORTICOID; IPRATROPIUM BROMIDE; LONG ACTING DRUG; MUCOLYTIC AGENT; MUSCARINIC M3 RECEPTOR ANTAGONIST; OXITROPIUM BROMIDE; PHOSPHODIESTERASE IV INHIBITOR; PROTEINASE; PROTEINASE INHIBITOR; REVATROPATE; ROFLUMILAST; ROLIPRAM; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZILEUTON;

ASTHMA; BRONCHODILATING ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; EXERCISE; HUMAN; LONG TERM CARE; LUNG FUNCTION; META ANALYSIS; MUCUS SECRETION; NAUSEA; NONHUMAN; OXIDATIVE STRESS; QUALITY OF LIFE; RESPIRATORY TRACT INFLAMMATION; SINGLE DRUG DOSE; VOMITING;

EID: 0036626931     PISSN: 11220643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (56)

1. Anto JM, Vermiere P, Vestbo J, Sunyer J. - Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001; 17: 982-995.
2. Murray CJ, Lopez AD. - Alternative projections of mortality and disability by cause. 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504.
3. Pawels RA, Löfdhal CG, Latinen LA, Schouten JP, Postma DS, Pide NB, Ohlsson SV. - Long-term treatment with inhaled budesonide in persons with mild chronic pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948-1953.
4. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. - Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 1999; 353: 1819-1823.
5. Hurt RD, Sachs DPL, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallay MA, Scroeder R, Glover PN, Sullivan CR, Croghan IT, Sullivan PM. - A comparison of sustained-release bupropion and placebo for smoking cessation. N Eng J Med 1997; 337: 1195-1202.
6. GOLD - Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease - NHLBI/WHO-Workshop Report.
7. Ferguson GT. - Recommendations for the management of COPD. Chest 2000; 117: 23S-28S.
8. Guyatt GH, Townsend M, Pugsley SO, Keller JL, Short HD, Taylor DW, Newhowse MT. - Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity, and quality of life. Am Rev Respir Dis 1987; 135: 1069-1074.
9. Ikeda A, Nishimura K, Kayama H, Tsukino M, Mishima M, Izumi T. - Dose response study of ipratropium bromide aerosol on maximum exercise performance in stable patients with chronic obstructive pulmonary disease. Thorax 1996; 51: 48-53.
10. O'Donnell DE, Lam M, Webb KA. - Measurement of symptoms, lung hyperinflation and endurance during exercise in chronic obstructive lung diseases. Am J Respir Crit Care Med 1998; 158: 1557-1565.
11. Liesker JJW, Wijkstra PJ, Ten Hacken NHT, Koeter GH, Postma DS, Kerstjens HAM. - A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD. Chest 2002; 121: 597-608.
12. 2-agonists in the management of stable chronic obstructive pulmonary disease. Drugs 2000; 60: 307-320.
13. Jones PW, Bosh TK. - Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283-1289.
14. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Richard KA, Anderson WH. - Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-965.
15. COMBIVENT Inhalation Aerosol Study Group. - In chronic obstructive pulmonary diseases a combination of ipratropium and albuterol is more effective then either agents alone. An 85-day multicenter trial. Chest 1994; 105: 1411-1419.
16. COMBIVENT Inhalation Solution Group. - Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997; 112: 1514-1521.
17. American Thoracic Society: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152 (suppl): S77-S120.
18. Alabaster VA. - Discovery and development of selective M3 antagonists for clinical use. Life Sci 1997; 60: 1053-1060.
19. Barnes PJ. - Tiotropium bromide. Expert Opin Investig Drugs 2001; 10: 733-740.
20. Barnes PJ, Belvisi MG, Mak JC, Haddad E, O'Connor B. - Tiotropium bromide (Ba 679 BR) a novel long-acting muscarinic antagonist for the treatment of obstructive airway disease. Life Sci 1995; 56: 853-859.
21. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T Jr. - A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-224.
22. Vincken W, Van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, Cornelissen PJ. - Improved health outcomes in patients with chronic obstructive pulmonary disease during 1 year's treatment with tiotropium. Eur Respir J 2002; 19: 209-216.
23. Barnes PJ. - Mechanisms of COPD: Differences from asthma. Chest 2000; 117: 10s-14s.
24. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA. - Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999; 340: 1941-1947.
25. O'Brien A, Ward NS. - Steroid therapy in chronic obstructive pulmonary disease. Med Health R 2002; 85: 52-55.
26. Siafakas NM, Vermiere P, Price NB, et al. - Optimal assessment and management of chronic pulmonary disease (COPD): The European Respiratory Society Task Force. Eur Respir J 1995; 8: 1398-1420.
27. BTS guidelines for the management of chronic obstructive pulmonary disease: The COPD Guideline Group of the Standard Care Committee of the BTS. Thorax 1997; 52(suppl 5): S1-S28.
28. Barnes PJ. - Novel approaches and targets for treatment of COPD. Am J Respir Crit Care Med 1999; 160: s72-s79.
29. Spina D. - The potential of PDE4 inhibitors in asthma or COPD. Curr Opin Investig Drugs 2000; 1: 204-213.
30. Dyke HJ, Montana JG. - Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs 2002; 11: 1-13.
31. Barnete MS, Underwood DC. - New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease. Curr Opin Pulm Med 2002 6: 164-169.
32. Giembycz MA. - Cilomilast: A second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2001; 10: 1361-1379.
33. Compton CH, Gubb J, Nieman R, Edelson J, Amit O, Baks A, Ayres JG, Creemers JP, Schultze-Werninghau G, Brambilla C, Barnes NC. - Cilomilast, a selective phosphodiesterase 4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: A randomised, dose-ranging study. Lancet 2001; 358: 256-270.
34. Zussman BD, Benincosa LJ, Webber DM, Clark DJ, Cowley H, Kelly J, Murdoch RD, Upward J, Wyld P, Port A, Fuder H. - An overview on the pharmacokinetics of cilomilast (Ariflo), a new orally active phosphodiesterase 4 inhibitor, in healthy young and elderly volunteers. J Clin Pharmacol 2001; 41: 950-958.
35. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R. - In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE inhibitor. J Pharmacol Exp Ther 2001; 297: 280-290.
36. MacNee W, Raham I. - Oxidants and antioxidants as therapeutic target in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: S58-S65.
37. Raham I, MacNee W. - Role of oxidants/antioxidants in smoking-induced lung diseases. Free Radical Biol Med 1996; 21: 669-681.
38. Smith CAD, Harrison DJ. - Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet 1997; 350: 630-633.
39. MacNee W, Bridgeman MME, Marsden E, Drost E, Lannan S, Selby C, Donaldson K. - The effect of N-acetylcysteine and glutathione on smoke-induced changes in lung phagocytes and epithelial cells. Am J Med 1991; 90: 60s-66s.
40. Nahy AM, Vanderbist F, Parij N, Maes P, Fondu P, Neve J. - Effect of the mucoactive drug nacystelyn on the respiratory burst of human blood polymorphonuclear neutrophils. Pulm Pharmacol Ther 1997; 10: 287-292.
41. Keatings VM, Collins PD, Scott DM, Barnes PJ. - Differences in interleukin 8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153: 530-534.
42. Owens C. - Chemokine receptors in airway disease; Which receptor to target? Pulm Pharmacol Ther 2001; 14: 193-202.
43. Underwood DC, Osborn RR, Bochnowicz S, Webb EF, Rieman DJ, Lee JC, Romanic AM, Adams JL, Hay DW, Griswold DE. - Sb 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol 2000; 279: L895-902.
44. Stockley RA. - New approaches for the management of COPD. Chest 2000; 117: 58S-62S.
45. Fujie K, Shinguh Y, Inamura N, Yasumitsu R, Okamoto M, Okuhara M. - Release of neutrophil elastase and its role in tissues injury in acute inflammation: Effect of the elastase inhibitor, FR 134043. Eur J Pharmacol 1999; 347: 117-125.
46. Hiemstra PS, Van Wetering S, Stolk J. - Neutrophil serine proteinases and defensins in chronic obstructive pulmonary disease: Effects on pulmonary epithelium. Eur Respir J 1998; 12: 1220-1228.
47. Cadene M, Duranton J, North A, Si-Tahar M, Chignard M, Bieth JG. - Inhibition of neutrophil serine proteinases by suramin. J Biol Chem 1997; 272: 9950-9955.
48. Ohbayashi H. - ZD-0892 Astra Zeneca. Curr Opin Investig Drugs 2000; 1: 227-229.
49. Veale CA, Nernstain PR, Bohnert CM, Brown FJ, Bryant C, Damewood JR, et al. - Orally active trifluormethyl ketone inhibitors of human leukocyte elastase. J Med Chem 1997; 40: 3173-3181.
50. Rogers DF. - Mucus pathophysiology in COPD: Difference to asthma and pharmacotherapy. Monaldi Arch Chest Dis 2000; 55: 324-332.
51. 1 decline and chronic obstructive lung diseases morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153: 1530-1535.
52. Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P. - Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. Thorax 1990; 45: 579-585.
53. Rogers DF. - Mucoactive drugs for asthma and COPD: Any place in therapy? Expert Opin. Investig Drugs 2002; 11: 15-35.
54. Poole PJ, Black PN. - Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. CD0012872000.
55. Poole PJ, Black PN. - Oral mucolytic drugs for exacerbation of chronic obstructive lung disease: Systematic review. BMJ 2001; 322: 1271-1274.
56. Grandjean EM, Berthet P, Ruffmann R., Leuenberger P. - Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: A meta-analysis of published double-blind placebo controlled clinical trials. Clin Ther 2000; 22: 209-221.